Enabling targeted infectious disease diagnostics across India through Genomics, Bioinformatics, and Machine Learning.
Targeted NGS
High-Throughput Sequencing
Bioinformatics
Variant & AMR Calling Pipelines
< 24h
Sample Turnaround Time
ISO Ready
Clinical AI & Quality Standards
Infectious disease management requires rapid identification at the genomic level. Micro Biomics combines target genomic sequencing with computational bioinformatics to convert raw genomic reads into actionable clinical insights.
Targeted Diagnostic Panels for High-Burden Pathogens
Antimicrobial Resistance (AMR) Profiling
Outbreak Tracking & Hospital-Acquired Infection Surveillance
Our pipeline architecture scales across multiple clinical applications:
Engineered specifically for clinical diagnostic labs, tertiary care hospitals, research networks, and public health infrastructure.
Comprehensive whole-genome & targeted mutation mapping for multi-drug resistant Mycobacterium tuberculosis.
Clinical WorkflowGenomic marker detection providing real-time susceptibility insights to optimize targeted antibiotic therapy.
AMR PipelineICU and ward surveillance pipelines for rapid outbreak tracking, strain typing, and pathogen containment.
Surveillance SystemEnd-to-end sample-to-report bioinformatics pipeline designed for scalable clinical diagnostic laboratories.
Diagnostic StackA unified system bridging wet-lab NGS data processing with clinical-grade decision support algorithms.
Raw FASTQ/BAM ingestion from Illumina, Oxford Nanopore, and target sequencing platforms with automated quality control checks.
Automated variant calling, phylogenetic alignment, and machine learning models trained on national pathogen mutation repositories.
Instant delivery of formatted clinical reports detailing identified pathogens, drug resistance profiles, and treatment options.
Demonstrating high accuracy in predicting resistance phenotypes prior to culture-based antibiotic susceptibility test completion.
Published by Micro Biomics Scientific TeamReducing turnaround times from weeks to under 24 hours for complex multi-drug resistant Mycobacterium tuberculosis.
Clinical Pilot Validation StudyWe work alongside hospital networks, commercial diagnostic laboratories, government bodies, and academic researchers to deploy state-of-the-art genomics pipelines.
